CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
No Chemotherapy in Intermediate-risk HR + HER2- Early Breast Cancer Treated with Ribociclib (NoLEEta)
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
Reminder: Feedback request on Health Canada Guidance GUI-0100 due April 2, 2018
The Central Operations and Statistics Office located at Queen's University in Kingston, Ontario has current job openings for two Study Coordinators and a Monitor/Auditor. Please visit our career page to find out more about these roles and how to apply.
Congratulations to our colleague Dr. Frances Shepherd, medical oncologist at Princess Margaret Cancer Centre, who has received the prestigious 2018 Canada Gairdner Wightman Award "for her global leadership in oncology which has contributed significantly to the improving survival outcome of lung cancer patients worldwide." Dr. Shepherd served as Chair of the Lung Cancer Committee at CCTG for 19 years!
The MAC.23 trial a Phase III Randomized Trial of Hypofractionated Post-Mastectomy Radiation with Breast Reconstruction has been centrally activated
On-line Registration is now open. Travel and hotel information, a draft Schedule of Events, and our meetings policies, including the Invitation Policy, Registration Policy, and Travel Reimbursement Policy, are posted on the Spring Meeting 2018 Registration and Information page.
Queen's University played host to a research funding announcement with Dr. John Fisher, Vice-Principal (Research), Queen’s University and Ms. Sophie Kiwala, MPP for Kingston and the Islands. Along with a number of awards, it was announced that CCTG has received matching infrastructure funding from The Ontario Research Fund to support the purchase of a histology slide scanner.
